Bridgepoint Group (LON:BPT) Stock Rating Reaffirmed as Buy by Jefferies Financial Group

Bridgepoint Group (LON:BPT)‘s stock had its “buy” rating reissued by research analysts at Jefferies Financial Group in a note issued to investors on Thursday, Digital Look reports. They presently have a GBX 485 price objective on the stock. Jefferies Financial Group’s price objective suggests a potential upside of 19.46% from the company’s previous close.

Separately, Berenberg Bank reissued a “buy” rating and set a GBX 360 target price on shares of Bridgepoint Group in a research report on Friday, September 18th. Four investment analysts have rated the stock with a Buy rating. According to MarketBeat, Bridgepoint Group presently has a consensus rating of “Buy” and a consensus target price of GBX 413.75.

Bridgepoint Group Stock Down 1.5%

Bridgepoint Group stock traded down GBX 6 during mid-day trading on Thursday, reaching GBX 406. The stock had a trading volume of 2,373,991 shares, compared to its average volume of 7,565,838. The company has a debt-to-equity ratio of 53.71, a quick ratio of 3.60 and a current ratio of 16.31. Bridgepoint Group has a fifty-two week low of GBX 212 and a fifty-two week high of GBX 416.20. The stock’s 50-day simple moving average is GBX 324.30 and its 200-day simple moving average is GBX 286.80. The firm has a market capitalization of £3.66 billion, a PE ratio of 135.33, a price-to-earnings-growth ratio of 0.61 and a beta of 1.39.

About Bridgepoint Group

Bridgepoint Group plc is a private equity and private credit firm specializing in middle market, small mid cap, small cap, growth capital, buyouts investments, syndicate debt, infrastructure, direct lending and credit opportunities in private credit investments. It prefers to invest in advanced industrials, automation, agricultural sciences, energy transition enablers, business services, financial services, professional services, testing inspection and certification, information services, consumer, digital brands, video games, wellbeing products, health care, pharma and MedTech outsourced services, pharma products, and MedTech Products sectors.